4596

Kubota Pharmaceutical Holdings Co., Ltd.

窪田製薬ホールディングス株式会社
Pharmaceutical
Kubota Pharmaceutical Holdings Co., Ltd. engages in the pharmaceutical and medical device business worldwide. The company offers eyeMO, a remote retinal monitoring device for home-based and patient self-monitoring optical coherence tomography; and a NASA high-res version OCT device. It also provides Emixustat HCI compounds for Stargardt disease indications in Phase 3 clinical trials, as well as proliferative diabetic retinopathy and diabetic macular edema in Phase 2 clinical trials. The company was founded in 2002 and is headquartered in Minato, Japan.
← Companies
Price
¥59
Market Cap
¥6.8B
Ent. Value
—
Net Cash est
—
Shares Out.
115.4M
P / E
—
EV / EBIT
—
P / Book
—
P / NCAV
3.78×
Div. Yield
—
Financials
Metric FY 2025
EDINET ↗ 		FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥21M ¥27M ¥40M ¥8M —
Cost of Sales ¥26M ¥5M ¥12M ¥6M —
SG&A ¥543M ¥711M ¥633M ¥601M —
Operating Income ¥-895M ¥-1.3B ¥-1.5B ¥-2.0B ¥-2.6B
Non-Operating Income ¥2M ¥6M ¥14M ¥18M ¥11M
Non-Operating Expenses ¥1M ¥7M ¥9M ¥12M ¥18M
Pre-tax Income ¥-676M ¥-1.3B ¥-1.5B ¥-2.0B ¥-2.6B
Net Income (owners) ¥-676M ¥-1.3B ¥-1.5B ¥-2.0B ¥-2.6B
Comprehensive Income ¥-670M ¥-1.3B ¥-1.5B ¥-1.7B ¥-2.2B
EPS ¥-10.59 ¥-23.65 ¥-26.79 ¥-40.92 ¥-57.46
Shares Outstanding 115.4M 56.8M 56.1M 54.6M 45.9M
Shares Issued (total) 115.4M 56.8M 56.1M 54.6M 45.9M